Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

May 31, 2004

Study Completion Date

September 30, 2005

Conditions
Urinary Tract Infections
Interventions
DRUG

Cipro XR (Ciprofloxacin, BAYQ3939)

Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days

Trial Locations (35)

11758

North Massapequa

33027

Pembroke Pines

34474

Ocala

35206

Birmingham

35209

Birmingham

35801

Huntsville

38119

Memphis

46202

Indianapolis

50309

Des Moines

63125

St Louis

78229

San Antonio

82001

Cheyenne

85258

Scottsdale

87102

Albuquerque

87109

Albuquerque

89109

Las Vegas

90015

Los Angeles

90201

Cudahy

90503

Torrance

90806

Long Beach

92103

San Diego

92653

Laguna Hills

97401

Eugene

93720-0153

Fresno

91942-3058

La Mesa

06708

Waterbury

52242-1089

Iowa City

02472

Watertown

89511-2069

Reno

07918

East Orange

11030-1961

Manhasset

12180-1695

Troy

19107-5096

Philadelphia

23249-0002

Richmond

98431-5000

Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY